2015
Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis
Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. Journal Of The National Cancer Institute 2015, 107: djv275. PMID: 26424778, PMCID: PMC4715249, DOI: 10.1093/jnci/djv275.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancer-specific mortalityCancer-specific mortalityCause mortalityWeight gainBreast cancer diagnosisBreast cancerStage I-IIIC breast cancerSystematic reviewPrediagnosis body mass indexWomen age 18 yearsPostdiagnosis weight gainCancer diagnosisCause mortality ratesBreast cancer mortalityAge 18 yearsWeb of ScienceCohort studyRecurrence outcomesMass indexCancer mortalityClinical trialsHigh riskMortality rateBody weight
1990
A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury
Bracken M, Shepard M, Collins W, Holford T, Young W, Baskin D, Eisenberg H, Flamm E, Leo-Summers L, Maroon J, Marshall L, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. New England Journal Of Medicine 1990, 322: 1405-1411. PMID: 2278545, DOI: 10.1056/nejm199005173222001.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNeurologic recoverySafety of methylprednisoloneSystematic neurological examinationPlacebo-controlled trialHours of injuryMajor morbidityNeurologic outcomeControlled TrialsNeurological examinationIncomplete lesionsMotor functionMethylprednisoloneNaloxonePatientsBody weightSensory functionInjuryPlaceboInfusionBolusEffective remainsTreatmentDose